Literature DB >> 6883909

Disopyramide kinetics in renal impairment: determinants of interindividual variability.

M Burk, U Peters.   

Abstract

Disopyramide kinetics were studied in 30 patients with normal to severely impaired renal function (endogenous creatinine clearance 7.6 to 116.9 ml/min/1.73 m2) after intravenous bolus injection. Serum concentration-time curves were fitted to an open two-compartment model. There was close correlation between renal disopyramide clearance and creatinine clearance (r = 0.922). Disopyramide body clearance or elimination rate constant (kel beta) and creatinine clearance did not correlate as closely (r = 0.756 and 0.644). Volume of distribution at steady state and extrarenal clearance of disopyramide both correlated slightly positively with renal function. Disopyramide body clearance and volume of distribution, but not kel beta, were found to be dose dependent. Disopyramide kinetics in renal impairment were not sufficiently predictable from clinical data of the patient because of great interindividual variation in drug disposition and renal and extrarenal elimination. Dosage regimen must therefore be based on individual response and controlled by the clinical effect and estimates of disopyramide serum concentration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883909     DOI: 10.1038/clpt.1983.176

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Kinetics of disopyramide in decreased hepatic function.

Authors:  J Bonde; N A Graudal; L E Pedersen; S Balsløv; H R Angelo; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 4.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

5.  Atenolol inhibits the elimination of disopyramide.

Authors:  J Bonde; S Bødtker; H R Angelo; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Plasma free fatty acids and protein binding of disopyramide during haemodialysis.

Authors:  T Horiuchi; I Johno; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.